| Literature DB >> 33614909 |
Hongliang Liu1,2,3,4,5, Yu Zhang4,6, Li Li5, Jimin Cao4,6, Yujia Guo1,2, Yongyan Wu1,2,3,4,7, Wei Gao1,2,3,4,5.
Abstract
Fascin actin-bundling protein 1 (FSCN1) is a highly conserved actin-bundling protein that cross links F-actin microfilaments into tight, parallel bundles. Elevated FSCN1 levels have been reported in many types of human cancers and have been correlated with aggressive clinical progression, poor prognosis, and survival outcomes. The overexpression of FSCN1 in cancer cells has been associated with tumor growth, migration, invasion, and metastasis. Currently, FSCN1 is recognized as a candidate biomarker for multiple cancer types and as a potential therapeutic target. The aim of this study was to provide a brief overview of the FSCN1 gene and protein structure and elucidate on its actin-bundling activity and physiological functions. The main focus was on the role of FSCN1 and its upregulatory mechanisms and significance in cancer cells. Up-to-date studies on FSCN1 as a novel biomarker and therapeutic target for human cancers are reviewed. It is shown that FSCN1 is an unusual biomarker and a potential therapeutic target for cancer.Entities:
Keywords: FSCN1; biomarker; cancer; metastasis; therapeutic target
Year: 2021 PMID： 33614909 PMCID： PMC7873579 DOI： 10.1016/j.omto.2020.12.014
Source DB: PubMed Journal: Mol Ther Oncolytics ISSN： 2372-7705 Impact factor: 7.200